DTIL · Insider Trading
Precision BioSciences, Inc. Common Stock
Every open-market purchase and sale reported by DTIL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-30 | Stanley Frankel | Director | Buy | +1,000 | +$6.00K |
| 2026-09-29 | Melinda Brown | Director | Buy | +1,135 | +$7.12K |
| 2026-09-29 | Geno J Germano | Director | Buy | +2,609 | +$16.38K |
| 2026-06-05 | Shari Lisa Pire | Director | A | +20,979 deriv. | — |
| 2026-06-05 | Melinda Brown | Director | A | +20,979 deriv. | — |
| 2026-06-05 | Stanley Frankel | Director | A | +20,979 deriv. | — |
| 2026-06-05 | Kevin Buehler | Director | A | +20,979 deriv. | — |
| 2026-06-05 | Geno J Germano | Director | A | +20,979 deriv. | — |
| 2026-06-03 | Dario Scimeca | General Counsel and Secretary | A | +107,604 deriv. | — |
| 2026-06-03 | John Alexander Kelly | Chief Financial Officer | A | +193,688 deriv. | — |
| 2026-06-03 | Michael Amoroso | President and CEO | A | +573,888 deriv. | — |
| 2026-06-03 | J. Jefferson Smith | Chief Research Officer | A | +57,389 deriv. | — |
| 2026-05-22 | Kevin Buehler | Director | M | +21,000 | — |
| 2026-05-22 | Stanley Frankel | Director | M | +21,000 | — |
| 2026-05-22 | Shari Lisa Pire | Director | M | +21,000 | — |
| 2026-05-22 | Geno J Germano | Director | M | +21,000 | — |
| 2026-05-22 | Melinda Brown | Director | M | +21,000 | — |
| 2026-02-19 | Michael Amoroso | President and CEO | MIXED | +47,238 | −$78.95K |
| 2026-02-19 | Dario Scimeca | General Counsel and Secretary | MIXED | +11,742 | −$18.91K |
| 2026-02-19 | J. Jefferson Smith | Chief Research Officer | MIXED | +11,742 | −$18.91K |
| 2026-02-19 | John Alexander Kelly | Chief Financial Officer | MIXED | +19,435 | −$31.29K |
| 2026-01-22 | Dario Scimeca | General Counsel and Secretary | MIXED | +16,457 | −$35.68K |
| 2026-01-22 | John Alexander Kelly | Chief Financial Officer | MIXED | +29,150 | −$61.31K |
| 2026-01-22 | Michael Amoroso | President and CEO | MIXED | +80,579 | −$145.11K |
| 2026-01-22 | J. Jefferson Smith | Chief Research Officer | MIXED | +18,966 | −$41.11K |
| 2025-12-17 | Stanley Frankel | Director | Buy | +2,700 | +$12.69K |
| 2025-12-17 | Geno J Germano | Director | Buy | +3,000 | +$14.16K |
| 2025-12-17 | Melinda Brown | Director | Buy | +1,381 | +$6.86K |
| 2025-11-04 | John Alexander Kelly | Chief Financial Officer | MIXED | +2,302 | −$8.46K |
| 2025-11-04 | Michael Amoroso | President and CEO | MIXED | +6,035 | −$22.12K |
| 2025-11-04 | Dario Scimeca | General Counsel and Secretary | MIXED | +1,170 | −$4.32K |
| 2025-09-30 | Stanley Frankel | Director | Buy | +2,700 | +$13.42K |
| 2025-09-24 | Melinda Brown | Director | Buy | +1,400 | +$6.85K |
| 2025-07-08 | John Alexander Kelly | Chief Financial Officer | Sell | −14,827 | −$63.16K |
| 2025-06-27 | Kevin Buehler | Director | Buy | +5,076 | +$21.12K |
| 2025-06-27 | Melinda Brown | Director | Buy | +1,682 | +$6.96K |
| 2025-06-04 | Geno J Germano | Director | M | +9,826 | — |
| 2025-06-04 | Kevin Buehler | Director | M | +9,826 | — |
| 2025-06-04 | Melinda Brown | Director | M | +9,826 | — |
| 2025-06-04 | Michael Amoroso | President and CEO | A | +203,390 deriv. | — |
| 2025-06-04 | Shari Lisa Pire | Director | M | +9,826 | — |
| 2025-06-04 | J. Jefferson Smith | Chief Research Officer | A | +50,000 deriv. | — |
| 2025-06-04 | John Alexander Kelly | Chief Financial Officer | A | +82,750 deriv. | — |
| 2025-06-04 | Dario Scimeca | General Counsel and Secretary | A | +50,000 deriv. | — |
| 2025-06-04 | Stanley Frankel | Director | M | +9,826 | — |
| 2025-03-28 | Melinda Brown | Director | Buy | +1,839 | +$8.74K |
| 2025-03-28 | Kevin Buehler | Director | Buy | +4,523 | +$21.12K |
| 2025-03-27 | Geno J Germano | Director | Buy | +3,250 | +$17.23K |
| 2025-03-25 | Michael Amoroso | President and CEO | MIXED | +2,453 | −$5.36K |
| 2025-03-05 | Dario Scimeca | General Counsel and Secretary | MIXED | +647 | −$1.34K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Michael Amoroso | President and CEO | 263,951 | $2.44M |
| J. Jefferson Smith | Chief Research Officer | 129,857 | $1.20M |
| John Alexander Kelly | Chief Financial Officer | 125,883 | $1.16M |
| Dario Scimeca | General Counsel and Secretary | 61,382 | $566.60K |
| Kevin Buehler | Director | 49,137 | $453.57K |
| Geno J Germano | Director | 47,492 | $438.38K |
| Melinda Brown | Director | 45,481 | $419.82K |
| Stanley Frankel | Director | 41,478 | $382.87K |
| Shari Lisa Pire | Director | 35,028 | $323.33K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DTIL quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.